<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04106492</url>
  </required_header>
  <id_info>
    <org_study_id>SQ3370-001</org_study_id>
    <secondary_id>2020-0185</secondary_id>
    <nct_id>NCT04106492</nct_id>
  </id_info>
  <brief_title>Phase 1 Study of SQ3370 in Patients With Advanced Solid Tumors</brief_title>
  <official_title>A Multicenter Phase 1, Open-Label Study of SQ3370 in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shasqi, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shasqi, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy
      of SQ3370 in patients with cancer (solid tumors).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2020</start_date>
  <completion_date type="Anticipated">October 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of SQ3370, including determination of the maximum tolerated dose and the recommended Phase 2 dose.</measure>
    <time_frame>35 Days</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>SQ3370</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SQ3370</intervention_name>
    <description>SQ3370 consists of 2 components: SQL70, a prodrug-activating biomaterial and SQP33, a prodrug of Doxorubicin</description>
    <arm_group_label>SQ3370</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of an advanced local or metastatic solid tumor

          -  Adequate hematologic, hepatic, renal, and coagulation function

        Exclusion Criteria:

          -  Prior exposure to 225 mg/m2 of Dox HCl or DOXIL / CAELYX Â® or 450 mg/m2 of epirubicin
             HCl.

          -  CHF, severe myocardial insufficiency, or cardiac arrhythmia

          -  Any of the following within 28 days prior to Cycle 1 Day 1:

          -  Major surgery, as defined by the Investigator

          -  Radiotherapy

          -  Chemotherapy

          -  Currently enrolled in or discontinued from a clinical study involving an
             investigational agent or non-approved use of a drug or device, or concurrently
             enrolled in any other type of medical research judged not to be scientifically or
             medically compatible with this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Shasqi Clinical Operations</last_name>
    <phone>415-800-1376</phone>
    <email>clinicalstudies@shasqi.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Angeles Clinic &amp; Research Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>415-800-1376</phone>
      <email>clinicalstudies@shasqi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stanford Cancer Center</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>415-800-1376</phone>
      <email>clinicalstudies@shasqi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>415-800-1376</phone>
      <email>clinicalstudies@shasqi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vivek Subbiah, MD</last_name>
      <phone>713-563-0393</phone>
      <email>VSubbiah@mdanderson.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chris O'Brien Lifehouse</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>415-800-1376</phone>
      <email>clinicalstudies@shasqi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal North Shore Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>415-800-1376</phone>
      <email>clinicalstudies@shasqi.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>September 25, 2019</study_first_submitted>
  <study_first_submitted_qc>September 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 27, 2019</study_first_posted>
  <last_update_submitted>July 9, 2020</last_update_submitted>
  <last_update_submitted_qc>July 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sarcoma</keyword>
  <keyword>Cancer</keyword>
  <keyword>Tumor</keyword>
  <keyword>Soft Tissue Sarcoma</keyword>
  <keyword>Solid Tumor</keyword>
  <keyword>Doxorubicin</keyword>
  <keyword>Intratumoral</keyword>
  <keyword>Anthracycline</keyword>
  <keyword>Phase 1</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

